This webinar will be hosted live and available on-demand Wednesday, February 28, 2024 11:00 AM-12:00 PM Eastern Time (8:00 AM PT and 5:00 PM CET) As the demands and requirements for new antibodies continue to evolve, access to broader antibody sequence diversity coupled with a powerful screening technology is critical. Unlike hybridoma and display technologies […]
Explore Events Articles
We’re excited to announce that from December 13-16, Bruker Cellular Analysis will be an exhibitor at this year’s Antibody Engineering & Therapeutics Conference in San Diego. This premier event is dedicated to showcasing the latest advancements in antibody engineering, design, and selection. With a focus on diverse topics such as Neurodegenerative Diseases, Tumor Microenvironment in […]
The Protein & Antibody Engineering Summit (PEGS) International Conference, set to take place from November 14-16th at the Lisbon Congress Center in Lisbon, Portugal, is the largest protein & antibody engineering event in Europe, which has been described as “the best biologics technology meeting in Europe.” The team from Bruker Cellular Analysis will be at […]
Bruker Cellular Analysis will be participating in the upcoming Society for Immunotherapy of Cancer (SITC) Conference, scheduled to take place on November 1-5 at the San Diego Convention Center. This conference stands as a leading global event that unites experts from the field of immunotherapy to advance the science, discover breakthroughs, and educate the world […]
Although cellular immunotherapy can achieve good outcomes, only a small proportion of cancer patients are being treated via this approach, with extremely long waitlists. Furthermore, applying centralized manufacturing workflows to individualized products results in complex logistics, creating laborious and non-standardized processes that elevate drug costs. In this upcoming webinar on Thursday, October 26, 10:00-11:00 AM […]
Scientists often use classical immunization strategies and hybridoma technologies to generate antibodies. However, when producing antibodies against poorly immunogenic targets, such as membrane proteins with short extracellular domains, these approaches achieve limited antibody diversity, making it difficult for scientists to select good candidates for pharmaceutical development. Innovative approaches that combine RNA immunization and single cell […]
In the dynamic world of science and technology, Bruker Cellular Analysis is at the forefront, driving advancements in functional cell biology to improve human health. Our goal is to empower scientists to maximize the potential of every cell through pioneering optofluidic and proteomic technologies. We are excited to share our latest innovations and collaborations at […]
Biotherapeutics comprise a large portion of the treatment options for a wide range of conditions and account for almost half of drugs approvals in 2022. However, the pace of new biologic development has not grown in recent years in part because of the increasing complexity of drug targets and desired performance of these drugs. To […]
The convergence of optofluidics and proteomic barcoding technologies marks a significant milestone in the evolution of cancer immunotherapy research. These cutting-edge tools empower scientists to unravel the complexities of immune responses, cellular behaviors, and functional proteomics with unprecedented speed and precision. As the pursuit of personalized medicine gains momentum, these technologies offer promise in guiding […]
In both research and clinical settings, the ability to identify which immune cells in a person’s body contribute to either cancer progression or clearance and their target specificity is of critical importance. Moreover, a more thorough understanding of the biological properties of T cells that correlate with clinical outcome is required and can help guide […]